CIP
ANAB icon

Chartwell Investment Partners’s AnaptysBio ANAB Stock Holding History

Chartwell Investment Partners’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,851
Closed -$1.34M – 486
2018
Q1 		$1.34M Buy
+12,851
New +$1.45M 0.05% 346

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Chartwell Investment Partners's ANAB Position: Q2 2018 in Review

Chartwell Investment Partners sold out of AnaptysBio (ANAB) in Q2 2018, closing a stake of 12,851 shares — an estimated $1.34M sold.

Chartwell Investment Partners first reported a position in ANAB in Q1 2018 and held it in 1 quarter. The position peaked at $1.34M in Q1 2018. 124 funds tracked by Wall St. Rank hold ANAB as of Q2 2018.

  • Chartwell Investment Partners reported no remaining AnaptysBio position as of Q2 2018 after selling out during the quarter.
  • Chartwell Investment Partners sold 12,851 AnaptysBio shares in Q2 2018, an estimated $1.34M.
  • Chartwell Investment Partners first reported a position in AnaptysBio in Q1 2018 and held it in 1 quarter.
  • Chartwell Investment Partners's AnaptysBio position peaked at $1.34M in Q1 2018.
  • 124 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2018.

Based on Chartwell Investment Partners's 13F filing for Q2 2018, filed 9 Aug 2018.